secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001628280-23-026339
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion Q2 U.S. product revenue +49% to $20.3M; net loss narrows to $49.9M
---------------------------------------------------------------------------

- Total revenue $25.8M (+37% YoY); U.S. net product revenue $20.3M (+49% YoY) driven by 26% retail Rx growth.
- Net loss $49.9M ($0.46 per share) versus $66.3M ($1.05) in Q2 2022; R&D expenses fell 32% to $22.1M.
- Submitted FDA sNDAs and EMA application to expand NEXLETOL/NEXLIZET labels; approvals expected 1H 2024.
- Presented CLEAR Outcomes primary prevention analysis at ADA, published in JAMA, expanding addressable U.S. market to 70M patients.
- Cash and investments $138.5M as of June 30, 2023; full-year 2023 opex outlook reaffirmed at $225-245M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828023026339/0001628280-23-026339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828023026339/espr-20230801.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-026339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer